23 results
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
5 Oct 23
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
7:15am
on these trends and continuing to bring SYFOVRE to people living with this chronic disease.”
Highlights from the launch to date include:
Strong
8-K
EX-99.1
yhkdx5i
27 Oct 20
Sobi obtains global co-development and exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, a targeted C3 therapy
7:17am
424B5
9hi7n z0k0wzfovrns
9 Jan 20
Prospectus supplement for primary offering
5:25pm
424B5
tqw8 woegvx
7 Jan 20
Prospectus supplement for primary offering
4:19pm
8-K
EX-99.1
ac5d4g
16 Sep 19
Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes
5:17pm
8-K
EX-99.1
f8uun2 6eh
12 Sep 19
Apellis Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes
8:34am
8-K
EX-99.1
ch6c8 vhq61d8rrr
11 Sep 19
Apellis Pharmaceuticals Announces Proposed Private Offering of
5:13pm
424B5
igjrt zu0i6idyr
7 Mar 19
Prospectus supplement for primary offering
4:28pm
8-K
EX-99.1
tne7cm1k
7 Mar 19
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
4:15pm
424B5
6g7zlfh7wc9mi8rv 512
6 Mar 19
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
li3ovy gog
20 Dec 18
Apellis Provides Update on Its Phase 3 Program for Patients with Geographic Atrophy
7:00am